Trends of Gynecological Cancers in Turkey: Toward Europe or Asia?
- PMID: 28937544
- DOI: 10.1097/IGC.0000000000001026
Trends of Gynecological Cancers in Turkey: Toward Europe or Asia?
Abstract
Objective: The aim of this study was to evaluate nationwide gynecological cancer trends in Turkey.
Methods: National cancer registry data (2009-2013) of Turkish Ministry of Health were evaluated. Ovarian, cervical, endometrial, vulvar, vaginal, and tubal cancers are evaluated with respect to age of diagnosis, incidence rates within years, stage, histological distributions, and mortality rates. Data were collected from active cancer registry centers, which increased from 23% in 2009 to 47.5% coverage of the whole population by 2012, and mortality data (2010-2015) were obtained from the Turkish Statistical Institute.
Results: A total of 16,023 gynecological cancers were evaluated among 116,940 female patients with cancer (13.7%). Average incidence for gynecological cancers was 22.7 of 100,000, representing 8437 total new cases annually. Incidence changes within time were not statistically significant, when evaluated for each tumor type. Estimated risk of gynecological cancer development before the age of 80 years was 3.08% (95% confidence interval, 3.07-3.09). The most common gynecological cancers were uterine corpus cancers, which were followed by ovarian and cervical carcinomas. Ovarian and uterine cancer incidences were closer to European levels rather than Asian countries, whereas cervical cancer incidence was extremely low. Gynecological cancers constituted an important fraction of cancer-related mortality in women by comprising approximately 10.35% of cancer-related deaths. Mortality rates due to gynecological cancers did not show a statistically significant increase within years.
Conclusions: This is the first national cancer registry report to be published for gynecological cancers by the Turkish Governmental Department. As a result, Turkish gynecological cancer epidemiological data were consistent with the data obtained from European and developed countries rather than Asian countries, except for cervical cancer incidence, which is extremely low.
Similar articles
-
Trends of Gynecological Cancers in Turkey: Toward Europe or Asia?Int J Gynecol Cancer. 2017 Sep;27(7):1525-1533. doi: 10.1097/IGC.0000000000001026. Int J Gynecol Cancer. 2017. PMID: 28708790
-
Trends of Gynecological Cancers in Turkey: Toward Europe or Asia?Int J Gynecol Cancer. 2017 Oct;27(8S):S1-S9. doi: 10.1136/ijgc-00009577-201710001-00001. Int J Gynecol Cancer. 2017. PMID: 30819761
-
The Burden and Trends of Gynecological Cancers in Asia from 1980 to 2021, with Projections to 2050: A Systematic Analysis for the Global Burden of Disease Study 2021.Curr Oncol. 2025 May 23;32(6):298. doi: 10.3390/curroncol32060298. Curr Oncol. 2025. PMID: 40558241 Free PMC article.
-
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.Health Technol Assess. 2001;5(32):1-195. doi: 10.3310/hta5320. Health Technol Assess. 2001. PMID: 12065068
-
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.Health Technol Assess. 2001;5(28):1-110. doi: 10.3310/hta5280. Health Technol Assess. 2001. PMID: 11701100
Cited by
-
Prognostic Role of the C-Reactive Protein/Albumin Ratio in Patients With Gynecological Cancers: A Meta-Analysis.Front Oncol. 2021 Oct 28;11:737155. doi: 10.3389/fonc.2021.737155. eCollection 2021. Front Oncol. 2021. PMID: 34778051 Free PMC article.
-
Effectiveness and toxicity of metronomic oral cyclophosphamide for recurrent or platinum-refractory ovarian cancer: A meta-analysis.Heliyon. 2022 Aug 24;8(8):e10399. doi: 10.1016/j.heliyon.2022.e10399. eCollection 2022 Aug. Heliyon. 2022. PMID: 36082328 Free PMC article.
References
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials